[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thyroid-neoplasms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thyroid-neoplasms":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,49,78,162,185,213,238,270,303,329,363,392,429,458,482,504],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":28,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":4,"leadSponsor":45,"locationsCount":48},"100133389","prospective-comprehensive-molecular-analysis-of-endocrine-neoplasms-100133389",false,"NCT01005654","Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms","* INCLUSION CRITERIA:\n* Participants who have an endocrine neoplasm based on radiographic and biochemical testing, or histologically\u002Fcytologically proven lesions of the thyroid, parathyroid, adrenal, extra-adrenal endocrine nests, paragangliomas, neuroblastomas, gastrointestinal\n\ntrack and pancreas or participants with a described pre or potentially malignant condition that requires surgery or biopsy as a part of the standard of care treatment and\u002For follow up.\n\n* Participants referred to the Endocrine Consult Service on other protocols for surgical evaluation of endocrine disorders based on radiographic and biochemical testing, or histologically\u002Fcytologically proven lesions of the thyroid, parathyroid, adrenal, extra-adrenal endocrine nests, paragangliomas, neuroblastomas and pancreas.\n* Participants must have an ECOG performance score of 0-2.\n* Participants must have physical examination parameters within acceptable limits by standard of practice guidelines prior to biopsy or surgery.\n* Participants must be planning to undergo surgery or biopsy as part of their treatment plan. Note: Participants will not be enrolled exclusively for the procurement of tissue samples.\n* Age \\>= 4 years of age.\n\nEXCLUSION CRITERIA:\n\nNone.","ALL","4 Years",{"count":18,"type":19},2415,"ESTIMATED","OBSERVATIONAL","Background:\n\n* Endocrine neoplasms (tumors) are among the fastest growing tumors in incidence in the United States. Furthermore, it is often difficult to distinguish between benign or malignant tumors in cancers of the thyroid, parathyroid, adrenal gland, and pancreas. More research is needed to improve detection and treatment options for patients who develop these kinds of cancer.\n* Researchers are interested in studying the molecular changes that are involved in endocrine cancer development and growth. To collect a sample of tumor specimens and healthy tissue for further study, researchers are specifically looking for samples from participants who are scheduled for surgery or biopsy on endocrine tumors.\n\nObjectives:\n\n\\- To collect samples of precancerous, cancerous, and healthy tissue from individuals who are scheduled for surgery or biopsy of endocrine system tumors.\n\nEligibility:\n\n\\- Individuals who have a tumor in or around their thyroid, parathyroid, adrenal gland, pancreas, or any neuroendocrine tissue, and are scheduled for surgery at the National Institutes of Health Clinical Center.\n\nDesign:\n\n* Participants in this study will provide blood and urine samples prior to surgery.\n* During the surgery or biopsy, pieces of the tumor or precancerous growth and pieces of normal tissue near to the tumor will be removed for ongoing and future research. The rest of the tumor or growth will be sent for analysis.\n* After surgery, participants will receive routine care until discharge, and doctors will discuss possible treatment options. If there is an appropriate NIH protocol, participants may choose to be treated at the NIH.\n* After discharge, participants will return to the clinic for a routine postoperative check about 6 weeks following the operation, and then may be followed yearly at the Clinical Center or by phone.",[23,24,25,26,27],"Endocrine Tumors","Thyroid Neoplasms","Parathyroid Neoplasms","Adrenal Neoplasm","Neuroblastoma",[29,30,31,32,33,34,35,36,37],"Gene Expression","Epigenetic (methylation)","Tissues Histological Evaluations","Establishment of Tumor Cell Lines","Metabolite and Protein Expression","Natural History","Adrenal Cancer","Endocrine Tumor","Thyroid Cancer","RECRUITING","2026-06-13",{"date":41,"type":42},"2026-06-16","ACTUAL",{"date":44,"type":42},"2009-10-07",{"name":46,"class":47},"National Cancer Institute (NCI)","NIH",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":73,"leadSponsor":75,"locationsCount":48},"100638805","computer-vision-based-recognition-of-parathyroid-glands-and-recurrent-laryngeal-nerves-in-endoscopic-surgery-100638805","NCT07628543","Computer Vision-Based Recognition of Parathyroid Glands and Recurrent Laryngeal Nerves in Endoscopic Surgery","Prospective Multicenter Model Validation Study of the PTAIR Computer Vision Model for Recognition of Parathyroid Glands and Recurrent Laryngeal Nerves During Endoscopic Thyroid Surgery","PTAIR","Inclusion Criteria:\n\n1. Age 18 years or older.\n2. Patients with benign or malignant thyroid disease who are scheduled to undergo endoscopic thyroid surgery.\n3. Standardized recorder-based intraoperative video collection is planned during surgery.\n4. Patients agree to intraoperative video recording, de-identification, and research use.\n5. Basic perioperative clinical data are available.\n6. The participating center is able to follow the standardized procedures for video collection, data upload, data security, and annotation quality control.\n\nExclusion Criteria:\n\n1. Refusal to provide informed consent.\n2. Patients scheduled to undergo conventional open thyroid surgery.\n3. Standardized recorder-based intraoperative video collection cannot be performed.\n4. Intraoperative video quality is insufficient for model analysis or expert review.\n5. Key surgical phases are missing from the video recording.\n6. Expert annotation or review of the parathyroid glands or recurrent laryngeal nerves cannot be completed.\n7. Video de-identification fails.\n8. Severe missing perioperative clinical data.\n9. Other conditions judged by the investigators to be unsuitable for study inclusion.",{"count":58,"type":19},100,"This study aims to evaluate the performance of the PTAIR computer vision model for recognizing parathyroid glands and recurrent laryngeal nerves during endoscopic thyroid surgery. Multicenter intraoperative endoscopic surgery videos will be prospectively collected. Using the video recorder timeline as the unified time reference, the first recognition time of parathyroid glands and recurrent laryngeal nerves by PTAIR, junior physicians, and senior physicians will be recorded during surgery. The continuous recognition time of parathyroid glands and recurrent laryngeal nerves by PTAIR will also be recorded.\n\nThis study focuses on the recognition performance of PTAIR in real-world multicenter endoscopic thyroid surgery settings. At this stage, PTAIR will not be used to guide intraoperative surgical decision-making, and the study will not evaluate the effect of PTAIR on clinical outcomes. The collected video data will be used to assess the performance of PTAIR under different centers, surgeons, equipment conditions, and surgical field conditions, and may provide data support for future model optimization.",[61,24],"Thyroid Diseases",[55,63,64,65,66,67],"Computer Vision","Endoscopic Thyroid Surgery","Parathyroid Gland Recognition","Recurrent Laryngeal Nerve Recognition","Model Validation","NOT_YET_RECRUITING","2026-06-01",{"date":71,"type":42},"2026-06-05",{"date":69,"type":19},{"date":74,"type":19},"2028-05-31",{"name":76,"class":77},"Fujian Medical University","OTHER",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":15,"minAge":86,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":133,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":161},"100565188","phase-2-agnostic-therapy-in-rare-solid-tumors-100565188","NCT06638931","Agnostic Therapy in Rare Solid Tumors","Phase II Basket Study to Evaluate the Tissue-agnostic Efficacy of Anti-Programmed Cell Death Protein 1 (Anti-PD1) Monoclonal Antibody in Patients With Advanced Rare Tumors","ANTARES","Inclusion Criteria\n\n1. Age 18 years or older.\n2. Patients with immunohistochemistry for PD-L1 with a combined positive score (CPS) of 10 or higher.\n3. Patients with progression or intolerance to already approved and accessible treatments for the specific neoplasm and population.\n4. Documented disease progression radiologically after the last routine treatment.\n5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n6. Measurable lesion per RECIST v1.1. Lesions previously treated with radiotherapy can only be used as target lesions if they are confirmed to be progressing by imaging before enrollment.\n7. Male participants must meet at least one of the following conditions:\n\n   1. Considered infertile;\n   2. No fertile partner;\n   3. Has a fertile partner who agrees to follow contraceptive guidance throughout the study period and for at least 6 months after the last dose of Nivolumab;\n\n      and\n   4. Agrees to abstain from sperm donation throughout the study period and for at least 6 months after the last dose of Nivolumab.\n8. Female participants must meet at least one of the following conditions:\n\n   1. Considered infertile;\n   2. Agrees to follow contraceptive guidance throughout the study period and for at least 6 months after the last dose of Nivolumab;\n9. Estimated life expectancy greater than 12 weeks, as determined by the investigator or delegated sub-investigator.\n10. Preserved organ functions defined by:\n\n    * Absolute neutrophil count ≥ 1,000;\n    * Hemoglobin ≥ 8.0 g\u002FdL (patients may receive transfusions to reach this level);\n    * Platelet count ≥ 100,000;\n    * Total bilirubin ≤ 1.5 × Upper Limit of Normal (ULN), or ≤ 3.0 × ULN for patients with Gilbert's syndrome;\n    * Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤ 2.5 × ULN (≤ 5 × ULN in the presence of liver metastases);\n    * Creatinine clearance \\> 30 mL\u002Fmin (estimated by Cockcroft-Gault).\n11. Diagnosis of rare cancer (List I) confirmed by histopathological examination, with the possibility of including other types of rare tumors (incidence of less than 6 in every 100,000) after careful evaluation and approval by the study board.\n\n    * List I:\n\n      * Urachal adenocarcinoma\n      * Parathyroid carcinoma\n      * Nasopharyngeal epithelial tumors\n      * Fibrolamellar carcinoma of any primary site\n      * Angiosarcoma of any primary site\n      * Secretory breast carcinoma\n      * Anal cancer\n      * Metaplastic breast carcinoma\n      * Chromophobe renal carcinoma, Microphthalmia-associated Transcription Factor (MiT) family translocation renal carcinoma; renal carcinoma with Fumarate Hydratase (FH) or Succinate Dehydrogenase (SDH) deficiency\n      * Carcinosarcoma of any primary site\n      * Small intestine cancer\n      * Cholangiocarcinoma\n      * Sertoli-Leydig cell tumors\n      * Cervical cancer of non-epidermoid histology\n      * Tracheal epithelial tumors\n      * Non-cystadenoma salivary gland tumors\n      * Mesothelioma of any site\n      * Neuroblastoma\n      * Adrenal cancer\n      * Penile cancer\n      * Apocrine carcinoma\n      * Fibrosarcoma of any primary site\n      * Cancer of unknown primary site\n      * Hemangioblastoma of any primary site\n      * Thyroid cancer\n      * Hepatoblastoma\n      * Fallopian tube cancer\n      * Leiomyosarcoma of any primary site\n      * Vaginal cancer\n      * Neurofibrosarcoma of any primary site\n      * Gallbladder cancer\n      * Osteosarcoma of any primary site\n      * Bile duct cancer\n      * Clear cell endometrial carcinoma\n      * Yolk sac tumor of any primary site\n      * Non-epidermoid bladder cancer\n      * Vulvar cancer\n      * Kaposi's sarcoma\n      * Epithelial ovarian cancer\n      * Soft tissue sarcoma\n      * Urethral cancer\n      * Granulosa cell tumor of any primary site\n      * Cystadenoma carcinoma\n      * Primitive neuroectodermal tumor of any primary site\n      * Pure or mixed neuroendocrine tumors with neuroendocrine component\n      * Trophoblastic tumor\n\nExclusion Criteria\n\n1. Previous treatment lines with immunotherapy (immune checkpoint inhibitors).\n2. Pregnant or breastfeeding individuals.\n3. Limiting comorbidity, in the opinion of the investigator.\n4. Active infection.\n5. Major surgery within the last 4 weeks.\n6. Functional class II or greater heart failure.\n7. Myocardial infarction or stroke within the last 6 months.\n8. History of pulmonary fibrosis or pneumonitis.\n9. Autoimmune diseases, except for patients with vitiligo and\u002For controlled thyroid\u002Fhypothyroidism without the use of immunosuppressors.\n10. Second invasive primary tumor diagnosed in the last 3 years and\u002For with active disease, except for localized skin tumors (non-melanoma) that have been treated with curative intent.\n11. Patients with prolonged QT interval.\n12. Uncontrolled Central Nervous System (CNS) metastases. Patients who have previously received local treatment, such as radiotherapy, will be eligible if clinical and radiological stability is demonstrated in the 2 weeks prior to the start of treatment. Patients must not be using corticosteroids for managing CNS disease.\n13. Presence of meningeal carcinomatosis.\n14. Worsening renal and liver function in the 14 days prior to enrollment.\n15. History of solid organ transplantation with or without immunosuppression.\n16. Patients with untreated acquired immunodeficiency. Immunocompromised patients may be included as long as they do not have active opportunistic disease and\u002For active infection, after thorough clinical evaluation by the investigator or sub-investigator. HIV-positive patients must have documented undetectable viral load prior to inclusion.\n17. Chronic use of corticosteroids at doses greater than 10 mg\u002Fday of prednisone or equivalent. Patients with adrenal insufficiency of non-autoimmune etiology (e.g., previous bilateral adrenalectomy) may be included if they are clinically compensated with 10 mg\u002Fday of prednisone or equivalent or less.","18 Years",{"count":88,"type":19},28,"INTERVENTIONAL",[91],"PHASE2","The ANTARES study is a phase II basket trial designed to evaluate the tissue-agnostic efficacy of the monoclonal anti-PD1 antibody, nivolumab, in patients with advanced or metastatic rare tumors.\n\nThe study aims to treat rare malignancies with PD-L1 expression (CPS ≥ 10), regardless of the tumor's tissue type or location. Patients who have not responded to standard treatments will be included, and treatment will last for up to 12 months. The study will assess objective response, progression-free survival, and biomarkers such as PD-L1, ctDNA, and microvesicles, in a multicenter collaborative effort to provide innovative therapeutic options for this underrepresented population",[94,95,96,97,98,99,100,101,102,103,104,105,106,107,27,108,109,110,111,112,113,24,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132],"Urachal Cancer","Parathyroid Carcinoma","Fibrolamellar Carcinoma","Angiosarcoma","Secretory Carcinoma of Breast","Anal Neoplasms","Metaplastic Breast Carcinoma","Translocation Renal Cell Carcinoma","Carcinosarcoma","Small Intestine Neoplasms","Cholangiocarcinoma","Sertoli-Leydig Cell Tumor","Adenoid Cystic Carcinoma","Mesothelioma","Adrenal Gland Neoplasms","Penile Neoplasms","Apocrine Carcinoma","Fibrosarcoma","Cancer of Unknown Primary","Hemangioblastoma","Hepatoblastoma","Fallopian Tube Neoplasms","Leiomyosarcoma","Vaginal Neoplasms","Neurofibrosarcoma","Gallbladder Neoplasms","Osteosarcoma","Biliary Tract Neoplasms","Clear Cell Endometrial Cancer","Yolk Sac Tumor","Vulvar Neoplasms","Kaposi Sarcoma","Ovarian Epithelial Cancer","Soft Tissue Sarcoma","Urethral Neoplasms","Granulosa Cell Tumor","Primitive Neuroectodermal Tumor","Neuroendocrine Tumors","Trophoblastic Tumor",[134,95,135,96,97,136,137,100,138,102,139,104,140,141,142,143,107,27,26,144,110,111,112,113,37,114,145,116,146,118,147,120,148,122,123,149,150,125,126,127,151,129,106,130,131,132],"Urachal Adenocarcinoma","Nasopharyngeal Epithelial Tumors","Secretory Breast Carcinoma","Anal Cancer","Chromophobe Renal Carcinoma","Small Intestine Cancer","Sertoli-Leydig Cell Tumors","Non-Squamous Cervical Neoplasm","Tracheal Epithelial Tumors","Non-Adenoid Cystic Salivary Tumors","Penile Cancer","Fallopian Tube Cancer","Vaginal Cancer","Gallbladder Cancer","Biliary Tract Cancer","Non-Squamous Bladder Cancer","Vulvar Cancer","Urethral Cancer","2026-04-10",{"date":154,"type":42},"2026-04-15",{"date":156,"type":42},"2024-07-16",{"date":158,"type":19},"2028-05",{"name":160,"class":77},"Instituto do Cancer do Estado de São Paulo",8,{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":15,"minAge":86,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":89,"phases":171,"briefSummary":173,"conditions":174,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":48},"100533041","trail-study-feasibility-and-pilot-100533041","NCT06220656","TRAIL Study: Feasibility and Pilot","ThyRoid Active Monitoring and Intervention Longitudinal (TRAIL) Study: Feasibility and Pilot","Inclusion Criteria:\n\n* Participants must be ≥18 years of age.\n* Participants must be able and willing to provide informed consent or have a surrogate capable of providing same.\n* Participants must be absent of symptoms referable to the nodule: dysphagia or nodule physically visible and\u002For bothersome to patient.\n* Participants' thyroid nodule must have a TI-RADS rating of 4 or 5.\n* Participants thyroid nodule must be ≤2 cm in largest diameter.\n* Participants must be being considered for biopsy.\n* Participants with a prior history of papillary thyroid cancer are eligible.\n\nExclusion Criteria:\n\nPatients who fall into one of the following categories will NOT be eligible for this study:\n\n* Adults who are unable to provide informed consent.\n* Patients for whom biopsy is not a consideration.\n* Patients with a prior history of thyroid cancer other than papillary thyroid cancer.\n* Patients with a history of radiation to the neck.\n* Patients who are athyroidal (thyroid gland has been removed or patient has only lingual thyroid tissue).\n* Patients who have ultrasound evidence of one or more of the following:\n* Airway invasion of the nodule.\n* Nodule adjacency to\u002Finvading the recurrent nerve.\n* Extra-thyroidal invasion by the nodule.\n* Patients who have metastasis to cervical lymph nodes (confirmed by needle biopsy if ultrasound suspicious), distant metastases, if identified) testing not required, not usual care)\n* Patients who have already had a biopsy of the nodule being considered for inclusion in the study.\n\nTRAIL Pilot Integrated QRI: Inclusion\u002FExclusion Criteria\n\nInclusion Criteria for Study Patient Participants:\n\n* Participants must meet the eligibility requirements above and will be or have been approached about enrolling in the pilot study.\n* Participants must be willing to allow audio recorder presence and \u002F or willing to be interviewed by the QRI team.\n\nExclusion Criteria for Study Patient Participants:\n\n-Patients who are not willing to allow audio recorder presence and\u002For not willing to be interviewed by QRI team will be excluded from this study.\n\nInclusion Criteria for Study Staff Participants:\n\n* Staff must be willing to audio record their communications with patients about enrolling in the study.\n* Staff must be willing to participate in interviews with QRI team about their views of the study.\n\nExclusion Criteria for Study Staff Participants:\n\n-Staff members who are not willing to participate in audio taping of recruitment discussions and\u002For interviews with QRI team about their views of the study will be excluded.",{"count":170,"type":19},20,[172],"NA","This is a pilot study to compare two ways of managing newly identified thyroid nodules that are likely to be cancerous based on ultrasound result and which under usual care would undergo immediate biopsy.\n\nThe main goals of this pilot study are 1) compare anxiety at 6 months in each treatment arm using the validated instrument Anxiety-CA, 2) measure thyroid quality of life in each treatment arm\n\nParticipants will be randomized to one of two groups:\n\n1. immediate biopsy (usual care)\n2. Active monitoring (serial ultrasound based monitoring and close clinical follow-up)",[175,24,37],"Thyroid Nodule","2026-03-19",{"date":178,"type":42},"2026-03-23",{"date":180,"type":42},"2025-05-01",{"date":182,"type":19},"2027-06",{"name":184,"class":77},"Dartmouth-Hitchcock Medical Center",{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":15,"minAge":86,"maxAge":192,"enrollmentInfo":193,"targetDuration":4,"studyType":89,"phases":195,"briefSummary":196,"conditions":197,"keywords":201,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":48},"100627319","emdr-integrative-group-protocol-and-individual-treatment-for-patients-with-cancer-a-pilot-study-100627319","NCT07447089","EMDR Integrative Group Protocol and Individual Treatment for Patients With Cancer: A Pilot Study","Combination of the EMDR Integrative Group Protocol and Individual EMDR Treatment in Patients With Advanced Thyroid Cancer: A Pilot Study","Inclusion Criteria:\n\n* cancer diagnosis\n* PTSD (IES-R \\> 32)\n\nExclusion Criteria:\n\n* receiving specialized trauma therapy\n* receiving current psychiatric pharmacological treatment, unless the dosage has been stable for at least 2 months prior to enrollment","100 Years",{"count":194,"type":19},25,[172],"The main aim of the present process-outcome study is to evaluate the feasibility and the effects of an EMDR-IGTP-OTS group intervention on a sample of people with cancer, by using a process-outcome study design, with repeated measures.",[24,198,199,200],"Neoplasm","Post-traumatic Stress Disorder (PTSD)","Psychological Distress",[202,203],"Psychoncology","Cancer","2026-03-02",{"date":206,"type":42},"2026-03-04",{"date":208,"type":42},"2025-12-05",{"date":210,"type":19},"2026-12-05",{"name":212,"class":77},"Università Cattolica di Milano",{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":219,"eligibilityCriteria":220,"healthyVolunteers":11,"sex":15,"minAge":221,"maxAge":222,"enrollmentInfo":223,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":225,"conditions":226,"keywords":227,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":48},"100625230","response-to-neoadjuvant-treatment-in-locally-advanced-thyroid-cancer-100625230","NCT07419932","Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer","Biochemical, Radiological and Pathological Responses to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer: A Multicenter Study","NeoLATC","Inclusion Criteria:\n\n* Age ≥ 14 years at enrollment.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n* Histologically or cytologically confirmed thyroid carcinoma, including differentiated thyroid carcinoma (DTC), medullary thyroid carcinoma (MTC), poorly differentiated thyroid carcinoma (PDTC), and anaplastic thyroid carcinoma (ATC).\n* LATC defined as clinical stage T4N0-1 at baseline, as confirmed by a multidisciplinary thyroid oncology board.\n* For patients with distant metastasis, the potential benefit from surgical intervention must be documented by the treating team.\n* Presence of at least one measurable lesion, according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\n* Normal function of major organs.\n* Written informed consent obtained.\n\nExclusion Criteria:\n\n* Patients who refuse tumor tissue biopsy or surgery.\n* Prior thyroid or major neck surgery.\n* History of other treatments for cancer, including surgery, chemotherapy, radiotherapy, or molecular targeted therapy, that may affect the current treatment plan.\n* Concurrent active malignancies.\n* Uncontrolled systemic diseases, including diabetes, hypertension, etc.\n* Pregnancy or breastfeeding.","14 Years","80 Years",{"count":224,"type":19},120,"This multicenter observational study aims to evaluate the safety and efficacy of neoadjuvant therapy in patients with locally advanced thyroid cancer, focusing on imaging, biochemical, and pathological responses, as well as short-term surgical outcomes and long-term prognosis.",[37,24],[37,228,229],"locally advanced","Neoadjuvant Therapy","2026-02-12",{"date":232,"type":42},"2026-02-19",{"date":234,"type":42},"2025-12-23",{"date":236,"type":19},"2029-06-30",{"name":76,"class":77},{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":4,"eligibilityCriteria":244,"healthyVolunteers":11,"sex":15,"minAge":86,"maxAge":4,"enrollmentInfo":245,"targetDuration":4,"studyType":89,"phases":247,"briefSummary":248,"conditions":249,"keywords":250,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":48},"100581716","testing-a-web-based-intervention-for-radioactive-iodine-symptom-management-to-improve-health-related-quality-of-life-among-differentiated-thyroid-cancer-patients-100581716","NCT06853925","Testing a Web-based Intervention for Radioactive Iodine Symptom Management to Improve Health-related Quality of Life Among Differentiated Thyroid Cancer Patients","A Pilot Randomized Controlled Trial of the Use of a Website About Radioactive Iodine Symptom Management in Patients With Thyroid Cancer","Inclusion Criteria:\n\n* Age 18 or older (papillary or follicular carcinoma)\n* Diagnosed with differentiated thyroid cancer\n* Received radioactive iodine (RAI) treatment less than or equal to three years ago.\n* Mild to moderate symptoms of RAI\n* Able to provide informed consent in English\n* Access to a computer, tablet, or smartphone with internet connectivity\n\nExclusion Criteria:\n\n* A condition that precludes providing informed consent or completing study procedures (cognitive or psychiatric condition, hearing problems) as identified by the patient's physician or as assessed by a trained study team member.",{"count":246,"type":19},88,[172],"The goal of this clinical trial is to learn if adult patients diagnosed with differentiated thyroid cancer can easily use and benefit from an online tool aimed to provide patients with educational resources and symptom management strategies to improve their quality of life after radioactive iodine (RAI) treatment. The main questions it aims to answer are:\n\n1. Can patients easily use and benefit from the RAI Support intervention?\n2. Does RAI Support improve health-related quality of life (overall well-being) compared to usual care?\n\nThis research will help test better digital tools to support thyroid cancer survivors in managing their health after RAI treatment.\n\nResearchers will compare RAI Support to treatment as usual (a publicly available informational website about thyroid cancer) to see if RAI Support works to improve patients' overall well-being.\n\nParticipants will:\n\n1. Receive access to RAI Support or an informational website (treatment as usual) for four weeks.\n2. Use the assigned website once a week for up to four weeks.\n3. Complete two online questionnaires (an initial questionnaire and a final questionnaire after four weeks of using the assigned website) about symptoms related to RAI treatment, mood, and confidence in managing symptoms.\n4. Complete an optional 60 minute virtual interview about your experiencing using the assigned website.",[24],[251,252,253,254,255,256,257,258,259,260],"symptom burden","self efficacy","feasibility studies","internet-based intervention","pilot projects","neoplasms","radioactive iodine treatment","iodine radioisotopes","health-related quality of life","informational needs","2026-01-14",{"date":263,"type":42},"2026-01-16",{"date":265,"type":42},"2025-10-02",{"date":267,"type":19},"2027-02",{"name":269,"class":77},"Georgetown University",{"id":271,"slug":272,"hasResults":11,"nctId":273,"briefTitle":274,"officialTitle":274,"acronym":4,"eligibilityCriteria":275,"healthyVolunteers":276,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":277,"targetDuration":279,"studyType":20,"phases":4,"briefSummary":280,"conditions":281,"keywords":289,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":48},"100298073","genetic-analysis-of-pheochromocytomas-paragangliomas-and-associated-conditions-100298073","NCT03160274","Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions","Inclusion Criteria:\n\n* diagnosis of pheochromocytoma and or paraganglioma\n* family member with diagnosis of pheochromocytoma and or paraganglioma\n* diagnosis of a pheochromocytoma- and or paraganglioma-associated condition\n* family member with diagnosis of a pheochromocytoma- and or paraganglioma-associated condition\n\nExclusion Criteria:\n\n* unconfirmed diagnosis of pheochromocytoma and\u002For paraganglioma or associated condition",true,{"count":278,"type":19},2000,"30 Years","Pheochromocytomas and paragangliomas are neural crest-derived tumors of the nervous system that are often inherited and genetically heterogeneous. Genetic screening is recommended for patients and their relatives, and can guide clinical decisions. However, a mutation is not found in all cases. The aims of this proposal are to: 1) to map gene(s) involved in pheochromocytoma, and 2) identify genotype-phenotype correlations in patients with pheochromocytoma\u002Fparaganglioma of various genetic origins.",[282,283,284,285,286,287,24,288],"Pheochromocytoma","Paraganglioma","Inherited Cancer Syndrome","Associated Conditions","Kidney Neoplasms","Bone Cancer","Other Cancer",[290,291,292,293],"tumor suppressor gene","oncogene","mutation","susceptibility gene","2025-10-13",{"date":296,"type":42},"2025-10-15",{"date":298,"type":42},"2005-10-19",{"date":300,"type":19},"2030-12-31",{"name":302,"class":77},"The University of Texas Health Science Center at San Antonio",{"id":304,"slug":305,"hasResults":11,"nctId":306,"briefTitle":307,"officialTitle":307,"acronym":4,"eligibilityCriteria":308,"healthyVolunteers":11,"sex":15,"minAge":86,"maxAge":309,"enrollmentInfo":310,"targetDuration":4,"studyType":89,"phases":312,"briefSummary":313,"conditions":314,"keywords":316,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":48},"100595524","hybrid-endoscopic-hemithyroidectomy-and-targeted-ablation-for-bilateral-papillary-thyroid-carcinoma-100595524","NCT07033572","Hybrid Endoscopic Hemithyroidectomy and Targeted Ablation for Bilateral Papillary Thyroid Carcinoma","Inclusion Criteria:\n\n* Age 18-65 years.\n* Dominant-side PTC ≤1.5 cm suitable for endoscopic resection.\n* Contralateral nodule ≤7 mm located ≥2 mm from posterior capsule.\n* No radiologic lymph-node metastasis on contralateral side.\n* Written informed consent.\n\nExclusion Criteria:\n\n* Extrathyroidal extension, gross nodal or distant metastasis.\n* Prior neck surgery, prior RFA\u002Fethanol injection, or neck irradiation.\n* Pregnancy or lactation.\n* Serious comorbidities precluding anesthesia or follow-up.","65 Years",{"count":311,"type":19},60,[172],"This study evaluates a thyroid-function-preserving alternative to routine total thyroidectomy for bilateral papillary thyroid carcinoma (PTC). Eligible adults undergo remote-access gas-less axillo-breast endoscopic hemithyroidectomy with level VI dissection on the dominant side, followed by ultrasound-guided radiofrequency ablation (RFA) of a ≤7 mm contralateral focus during the same anesthesia. Outcomes include structural-recurrence-free survival, endocrine-function preservation, safety, and quality of life over 24 months.",[24,315],"Carcinoma, Papillary",[317,318,319,320],"Hybrid endoscopic thyroidectomy","Radiofrequency ablation","Thyroid function preservation","Bilateral Thyroid Carcinoma","2025-07-01",{"date":323,"type":42},"2025-07-03",{"date":325,"type":42},"2018-06-01",{"date":327,"type":19},"2028-06-30",{"name":76,"class":77},{"id":330,"slug":331,"hasResults":11,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":335,"eligibilityCriteria":336,"healthyVolunteers":11,"sex":15,"minAge":86,"maxAge":222,"enrollmentInfo":337,"targetDuration":4,"studyType":89,"phases":339,"briefSummary":340,"conditions":341,"keywords":345,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":360,"leadSponsor":362,"locationsCount":48},"100596247","peri-operative-bipap-to-prevent-tracheostomy-in-high-risk-bilateral-vocal-cord-paralysis-bvcp-100596247","NCT07042971","Peri-operative BiPAP to Prevent Tracheostomy in High-Risk Bilateral Vocal-Cord Paralysis (BVCP)","A Multicenter, Randomized Controlled Trial of Pre-operative BiPAP Training and Post-extubation BiPAP Support to Reduce Peri-operative Tracheostomy or Re-intubation in Patients at High Risk for Bilateral Vocal-Cord Paralysis","BVCP-BiPAP","Inclusion Criteria:\n\n* Age 18 - 80 years.\n* Scheduled for thyroidectomy or other neck surgery under general anesthesia.\n* High risk of bilateral vocal-cord paralysis (BVCP) defined by at least ONE of:\n\n  * Pre-operative flexible laryngoscopy showing fixed vocal cords at midline or paramedian position, or glottic gap ≤ 3 mm; OR\n  * Presence of ≥ 2 high-risk factors:\n\n    * Planned bilateral central plus lateral neck dissection\n    * Re-operative bilateral neck surgery or dense scarring\n    * Tumor involving both recurrent laryngeal nerves or crico-arytenoid joints\n    * Severe obstructive sleep apnea (AHI ≥ 30 events\u002Fhour)\n    * Body-mass index (BMI) ≥ 30 kg\u002Fm²\n* Able to tolerate and give informed consent for BiPAP mask use.\n\nExclusion Criteria:\n\n* Emergency surgery or need for immediate tracheostomy.\n* Existing tracheostomy or home ventilator dependence.\n* Inability to protect airway (e.g., Glasgow Coma Scale \\\u003C 13).\n* Craniofacial anomaly or skin condition precluding mask seal.\n* Pregnancy or breastfeeding.\n* Participation in another interventional trial that could interfere with study endpoints.",{"count":338,"type":19},204,[172],"Why: After thyroid or neck surgery, some patients can lose movement of both vocal cords (bilateral vocal-cord paralysis, BVCP). This can make breathing difficult and often leads to an emergency or preventive tracheostomy (\"wind-pipe\") surgery.\n\nWhat: This study will test two simple ways to avoid a tracheostomy:\n\nPre-operative BiPAP sleep training - patients practice sleeping with a non-invasive BiPAP breathing machine for seven nights before surgery so they become comfortable with the mask and pressures.\n\nImmediate post-extubation BiPAP support - the same BiPAP machine is started as soon as the breathing tube is removed in the operating room or recovery area.\n\nHow: Adults (18-80 years) who already have, or are at high risk of getting, BVCP will be randomly assigned to one of four groups in a 2 × 2 design:\n\n• Group 1: training + post-op BiPAP • Group 2: training only • Group 3: post-op BiPAP only • Group 4: standard care (no planned BiPAP).\n\nMain goal: To find out whether either or both BiPAP strategies reduce the need for tracheostomy or re-intubation during the first 7 days after surgery.\n\nWhat participants do: Eligible patients will undergo routine surgery plus the assigned BiPAP plan. Breathing events, comfort, hospital stay, and voice quality will be recorded up to 6 months.\n\nPotential benefit\u002Frisk: BiPAP is non-invasive and already FDA-cleared for home and hospital use, but some people may feel mask discomfort or air leaks. Trained staff will adjust settings and stop BiPAP if serious problems occur.",[342,343,24,344],"Vocal Cord Paralysis, Bilateral","Airway Obstruction, Postoperative","Sleep Apnea, Obstructive",[346,347,348,349,350,351,352,353,354,355],"BiPAP","Non-invasive Ventilation","Continuous Positive Airway Pressure","Peri-operative Airway Management","Tracheostomy Avoidance","Thyroidectomy","Neck Surgery","Glottic Stenosis","Pre-operative Sleep Training","Voice Handicap Index","2025-06-27",{"date":358,"type":42},"2025-06-29",{"date":321,"type":19},{"date":361,"type":19},"2029-12-31",{"name":76,"class":77},{"id":364,"slug":365,"hasResults":11,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":369,"eligibilityCriteria":370,"healthyVolunteers":11,"sex":15,"minAge":86,"maxAge":371,"enrollmentInfo":372,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":374,"conditions":375,"keywords":379,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":389,"completionDateStruct":390,"leadSponsor":391,"locationsCount":48},"100596248","ret-us-study---ultrasound-based-prediction-of-ret-alterations-and-lateral-neck-metastasis-in-thyroid-cancer-100596248","NCT07042984","RET-US Study - Ultrasound-Based Prediction of RET Alterations and Lateral-Neck Metastasis in Thyroid Cancer","RET-US Cohort: Prospective Evaluation of an AI-Ultrasound Model for Detecting RET Gene Alterations and Predicting Lateral Cervical Lymph-Node Metastasis in Papillary Thyroid Carcinoma","RET-US","Inclusion Criteria:\n\n* Age 18-75 years, able to provide written informed consent.\n* Pre-operative ultrasound findings highly suggestive of papillary thyroid carcinoma.\n* Planned thyroidectomy (any extent) at a participating institution.\n* Willing to undergo rapid 11-gene next-generation sequencing (NGS) panel and allow use of ultrasound DICOM images for AI analysis.\n\nExclusion Criteria:\n\n* Prior thyroid or major neck surgery.\n* Known medullary thyroid carcinoma, anaplastic carcinoma, or metastatic disease outside the neck.\n* Multiple endocrine neoplasia (MEN) syndromes or clinical suspicion of multi-gland disease.\n* Pregnant or breastfeeding.\n* Severe renal impairment (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²) or other condition that precludes surgery or gene testing.","75 Years",{"count":373,"type":19},800,"Why is this study being done? RET gene alterations occur in only 5-10 % of papillary thyroid cancers, but they can change how surgeons treat the disease. Gene testing is costly and not always performed, so many RET-positive tumours are missed. Researchers have built a computer program (artificial-intelligence or \"AI\" model) that reads routine thyroid ultrasound images and predicts whether the tumour carries a RET alteration and whether the cancer has already spread to lymph-nodes in the side of the neck.\n\nWhat will happen in this study?\n\nAbout 800 adults who are scheduled for thyroid-cancer surgery will take part. Each participant will:\n\n* have a standard pre-operative ultrasound exam (no extra scanning time),\n* give a routine fine-needle sample for a 14-gene panel test (results in 24 h), and\n* allow the AI model to analyse the ultrasound images in the background. Doctors making treatment decisions will not see the AI result. After surgery, the research team will compare the AI predictions with the gene-panel result and the final pathology report.\n\nMain goal: To find out how accurately the AI model detects RET alterations. Secondary goals: To measure the model's ability to predict lymph-node spread, and to compare costs between ultrasound-only prediction and full gene testing.\n\nBenefits and risks: Participants will receive the current standard of care; there is no added risk beyond the usual ultrasound and needle biopsy. The study could lead to faster, less expensive ways to identify high-risk thyroid cancers in the future.",[376,24,377,378],"Papillary Thyroid Carcinoma","RET Proto-Oncogene Mutation","Lymphatic Metastasis",[380,381,382,383,384,385,386],"Ultrasound Radiomics","Artificial Intelligence","RET Fusion","BRAF V600E","Lateral Neck Metastasis","Deep Learning Model","11-Gene Panel","2025-06-21",{"date":358,"type":42},{"date":321,"type":19},{"date":361,"type":19},{"name":76,"class":77},{"id":393,"slug":394,"hasResults":11,"nctId":395,"briefTitle":396,"officialTitle":397,"acronym":398,"eligibilityCriteria":399,"healthyVolunteers":11,"sex":15,"minAge":86,"maxAge":4,"enrollmentInfo":400,"targetDuration":402,"studyType":20,"phases":4,"briefSummary":403,"conditions":404,"keywords":407,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":422,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":427,"locationsCount":48},"100593741","dual-channel-near-infrared-autofluorescence-imaging-and-ai-analysis-to-locate-parathyroid-glands-ptfinder-100593741","NCT07010380","Dual-Channel Near-Infrared Autofluorescence Imaging and AI Analysis to Locate Parathyroid Glands (PTFinder)","A Multicenter Prospective Paired Observational Study Evaluating the Performance of the PTFinder Dual-Channel Near-Infrared and White-Light Imaging System With AI-Assisted Analysis for Rapid Identification of Parathyroid Glands in Surgical Specimens","PTFinder","Inclusion Criteria:\n\n* Age ≥18 years.\n* Scheduled for elective total thyroidectomy, hemithyroidectomy, or parathyroidectomy with removal of thyroid\u002Fparathyroid tissue.\n* Able and willing to provide written informed consent for participation and specimen imaging.\n\nExclusion Criteria:\n\n* History of neck irradiation or prior neck surgery that may distort parathyroid anatomy.\n* Pregnancy or breastfeeding.\n* Confirmed or suspected parathyroid carcinoma, or thyroid carcinoma requiring en-bloc parathyroid resection.\n* Inability to understand the study procedures or to comply with follow-up.",{"count":401,"type":19},180,"7 Days","This study tests PTFinder, a dual-camera system that makes parathyroid glands glow on screen by capturing their natural near-infrared autofluorescence. After a thyroid or parathyroid operation, the removed tissue is scanned with PTFinder and then checked again under normal white light. We will measure how fast (seconds) and how accurately the device finds real glands, confirmed by frozen pathology or a rapid PTH strip. About 180 adult patients at three Chinese hospitals will join. The imaging adds only a few minutes and does not change any part of the surgery. We will also record blood calcium and PTH at 1 h, 24 h, and 7 d after surgery to see whether better gland recovery lowers low-calcium risk.Collected images will also be used to train and test a deep-learning model for fully automated parathyroid recognition; model performance metrics constitute secondary outcomes.",[24,405,406],"Hyperparathyroidism","Parathyroid Gland",[408,409,410,411,412,413,414,415,381,416,63,417,418,419,420],"Near-Infrared Autofluorescence (NIRAF)","Parathyroid Identification","PTFinder Device","Dual-Channel Imaging","Rapid PTH Test Strip","Thyroidectomy Specimen","Ex-Vivo Fluorescence Camera","Sensitivity and Specificity","Deep Learning","NIRAF 3 Dual","PTFinder 3 Dual","PTFinder 3.0 Dual","NIRAF 3.0 Dual","2025-06-14",{"date":423,"type":42},"2025-06-18",{"date":425,"type":42},"2025-06-01",{"date":361,"type":19},{"name":428,"class":77},"Bo Wang,MD",{"id":430,"slug":431,"hasResults":11,"nctId":432,"briefTitle":433,"officialTitle":434,"acronym":4,"eligibilityCriteria":435,"healthyVolunteers":11,"sex":15,"minAge":86,"maxAge":222,"enrollmentInfo":436,"targetDuration":4,"studyType":89,"phases":438,"briefSummary":440,"conditions":441,"keywords":442,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":452,"startDateStruct":454,"completionDateStruct":455,"leadSponsor":457,"locationsCount":48},"100593742","phase-4-genotype-driven-neoadjuvant-therapy-for-locally-advanced-thyroid-cancer-a-real-world-cohort-study-100593742","NCT07010393","Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study","A Multicenter Prospective-Retrospective Real-World Study Evaluating Conversion-to-Surgery and Survival After Genotype-Matched Neoadjuvant Systemic Therapy in Locally Advanced Thyroid Carcinoma","Inclusion Criteria:\n\n1. Age ≥ 18 years at enrollment.\n2. Histologically or cytologically confirmed thyroid carcinoma that meets ≥ 1 of the following:\n\n   * Radioactive-iodine-refractory differentiated thyroid carcinoma (DTC)\n   * Medullary thyroid carcinoma (MTC)\n   * Anaplastic or poorly differentiated thyroid carcinoma (ATC\u002FPDTC)\n   * Other locally advanced \u002F metastatic thyroid malignancy deemed incurable by surgery alone.\n3. Disease judged unresectable or entailing prohibitively high-morbidity surgery at baseline by a multidisciplinary thyroid-oncology board.\n4. Documented molecular or immunophenotype qualifying for ≥ 1 study arm:\n\n   * BRAF V600E mutation\n   * RET gene fusion\n   * RET activating point mutation (e.g., M918T)\n   * NTRK1\u002F2\u002F3 fusion\n   * Isolated TERT-promoter mutation with no BRAF\u002FRET\u002FNTRK alterations\n   * Driver-negative \u002F VEGFR-wild type (\"triple-negative\")\n   * PD-L1 expression ≥ 1 % OR progression after prior multi-kinase inhibitor (MKI).\n5. ECOG Performance Status 0-2.\n6. At least one measurable lesion per RECIST v1.1 \u002F iRECIST (MTC with calcitonin\u002FCEA evaluable disease accepted).\n7. Written informed consent obtained.\n\nExclusion Criteria:\n\n1. Untreated or symptomatic CNS metastases; patients with treated, stable lesions ≥ 4 weeks and off corticosteroids are eligible.\n2. Pregnant or breastfeeding. Women and men of child-bearing potential must agree to effective contraception during study and for ≥ 120 days after last dose (≥ 180 days for men after dabrafenib\u002Ftrametinib).",{"count":437,"type":19},335,[439],"PHASE4","This multicenter registry tests whether genomically matched neoadjuvant therapy (1-4 cycles tailored to BRAF V600E, RET fusion\u002Fmutation, isolated TERT mutation, triple-negative BRAF\u002FRET\u002FTERT, or ICI ± TKI) can render locally advanced, initially unresectable-or high-morbidity-thyroid cancers operable. The primary endpoint is conversion-to-surgery; key secondaries are R0\u002F1 margin rate and 12-month event-free survival, with propensity-score weighting correcting cohort imbalances. Findings aim to define a precision-guided neoadjuvant standard for down-staging advanced thyroid tumors.",[24],[443,229,444,383,382,445,446,447,448,449,450,451],"Locally Advanced","Real-World Study","VEGF-TKI","Immunotherapy","Conversion Surgery","R0 Resection","Precision Oncology","Real-World Evidence","Conversion Therapy",{"date":453,"type":42},"2025-06-08",{"date":321,"type":19},{"date":456,"type":19},"2028-12-31",{"name":76,"class":77},{"id":459,"slug":460,"hasResults":11,"nctId":461,"briefTitle":462,"officialTitle":463,"acronym":464,"eligibilityCriteria":465,"healthyVolunteers":11,"sex":15,"minAge":86,"maxAge":466,"enrollmentInfo":467,"targetDuration":4,"studyType":89,"phases":469,"briefSummary":470,"conditions":471,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":473,"lastUpdatePostDateStruct":474,"startDateStruct":476,"completionDateStruct":478,"leadSponsor":480,"locationsCount":48},"100546734","dual-port-trans-subclavian-thyroid-endoscopic-surgery-100546734","NCT06398795","Dual-port Trans-subclavian Thyroid Endoscopic Surgery","Dual-port Trans-subclavian Thyroid Endoscopic Surgery - an Exploration of Cavity Construction in Situ Heralds a New Approach Choice","DTS","Inclusion Criteria:\n\n* Thyroid cancer or benign thyroid tumors\n* Patients with a demand for incisional cosmetic improvement\n\nExclusion Criteria:\n\n* Patients with thyroid cancer larger than 2 cm\n* benign tumors larger than 5 cm\n* Patients with severe underlying diseases\n* Patients with chronic kidney disease,\n* Patients with autoimmune diseases\n* Patients with rheumatoid arthritis","90 Years",{"count":468,"type":19},300,[172],"This is a prospective, single-center, open-label, non-randomized controlled real-world study aimed at exploring a novel approach to cavity construction for thyroid endoscopic surgery. The study seeks to evaluate its effectiveness and safety while accumulating further evidence-based medical data.\n\nThree hundred patients with thyroid tumors were divided into an experimental group (150 cases receiving a new endoscopic thyroid surgery technique, namely, dual-port trans-subclavian thyroid endoscopic surgery) and a control group (150 cases undergoing traditional open thyroid surgery) according to their treatment intention. Laboratory and medical data from specified follow-up points are collected, and adverse events are recorded detailly.\n\nThe primary efficacy endpoint is a comparison of surgical complications between the two treatment groups. Secondary endpoints include: (1) levels of IL-2, IL-4, IL-6, IL-10, TNF-α, INF-γ, renin, angiotensin II, and aldosterone preoperatively and on the second day postoperatively; (2) NRS scores on the first day postoperatively; (3) length of hospital stay, duration of surgery, total treatment cost, and postoperative drainage volume; and (4) assessment of wound satisfaction during a three-month follow-up visit.\n\nSafety assessments include adverse events, vital signs, and pathological examinations.",[24,472],"Endoscopic Surgery","2024-12-29",{"date":475,"type":42},"2024-12-31",{"date":477,"type":42},"2022-09-01",{"date":479,"type":19},"2026-12-31",{"name":481,"class":77},"First Affiliated Hospital of Wenzhou Medical University",{"id":483,"slug":484,"hasResults":11,"nctId":485,"briefTitle":486,"officialTitle":487,"acronym":4,"eligibilityCriteria":488,"healthyVolunteers":11,"sex":15,"minAge":86,"maxAge":371,"enrollmentInfo":489,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":491,"conditions":492,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":494,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":500,"locationsCount":503},"100515658","study-of-anlotinib-hydrochloride-capsules-in-the-treatment-of-locally-advanced-or-metastatic-radioiodine-refractory-differentiated-thyroid-carcinoma-100515658","NCT05994365","Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma","A Real-world Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma","Inclusion Criteria:\n\n* Patients voluntarily participate in this study, sign the informed consent form and had good compliance;\n* Aged 18 \\~ 70 years old; Eastern Cooperative Oncology Group Performance Status (ECOG PS) score: 0\\~1; more than 6 months of expected survival ;\n* Histopathologically confirmed locally advanced or metastatic differentiated thyroid cancer, radiographically documented disease progression within 18 months of absence of radioactive iodine (RAI) therapy;\n* Meet any of the following:\n\n  1. Lesions were not iodine-avid: no RAI uptake was confirmed after RAI scan in the presence of a low-iodine diet, adequate thyroid stimulating hormone (TSH) elevation (≥ 30 mIU\u002FL). The definition of no iodine uptake:\n\n     1. no iodine uptake initially;\n     2. exist of iodine uptake initially while lost subsequently;\n     3. partially uptake;\n     4. progression disease despite iodine uptake.\n  2. The cumulative dose of RAI was ≥ 600 mCi or 22 GBq, with an interval of at least 3 months.\n  3. Radiographically documented disease progression within 18 months of RAI therapy despite the presence of iodine-131 affinity at the time of RAI therapy;\n* At least one measurable lesion according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1.\n* Major organ functions meet the following criteria within 7 days prior to treatment:\n\n  1. Blood routine test criteria (14 days without blood transfusion):\n\n     1. Hemoglobin (HB) ≥ 85 g\u002FL;\n     2. Absolute neutrophil count (ANC) ≥ 1.5 × 10\\^9\u002FL;\n     3. Platelet (PLT) ≥ 80 × 10\\^9\u002FL\n  2. Biochemical tests need to meet the following criteria:\n\n     1. Total bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN);\n     2. Alanine aminotransferase (ALT) and aspartate aminotransferase AST ≤ 2 .5×ULN, ALT and AS if liver metastases T ≤ 5 ×ULN;\n     3. Serum creatinine (Cr) ≤ 1 .5 ×ULN or creatinine clearance (CCr) ≥ 60 Ml\u002Fmin;\n* Females of childbearing potential should agree to use contraceptive measures (such as intrauterine device, contraceptives or condoms) during the study and within 6 months after the end of the study; have a negative serum or urine pregnancy test within 7 days before study enrollment and must be non-lactating patients; and males should agree to use contraceptive measures during the study and within 6 months after the end of the study period.\n\nExclusion Criteria:\n\n* Comorbidities and medical history:\n\n  1. A history of or concurrent with other malignancies within the past 3 years. Patients were eligible if they had disease-free survival (DFS) for 5 consecutive years in other malignancies treated by single surgery; Cured cervical carcinoma in situ, non-melanoma skin cancer and superficial bladder tumors \\[Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor infiltrating basement membrane)\\];\n  2. Major surgical treatment, open biopsy, or significant traumatic injury within 28 days before the start of study treatment;\n  3. Subjects with any severe and\u002For uncontrolled illness, including:\n\n     1. Patients with ≥ grade 2 myocardial ischemia or myocardial infarction, arrhythmia (including Corrected QT Interval (QTc)≥450ms(male), QTc≥ 470ms(female)) and ≥ grade 2 congestive heart failure (NYHA classification);\n     2. Severe active or uncontrolled infection (≥ grade 2 infection according to Common Terminology Criteria for Adverse Events (CTCAE) );\n     3. Renal failure requiring hemodialysis or peritoneal dialysis;\n* Patients with concomitant diseases that seriously endanger the safety of patients or affect the completion of the study, or patients who are considered to be unsuitable for enrollment for other reasons according to the judgment of the investigators.\n* patients with previous treatment with anlotinib hydrochloride capsules or similar vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) small molecule drugs, such as vandetanib, Cabozantinib, lenvatinib, sunitinib, or sorafenib, etc.;",{"count":490,"type":19},380,"The study aims to observe and investigate the efficacy and safety of Anlotinib capsules in patients with locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma in the real world, and to summarize the treatment experience in a broad population.",[24],"2023-08-09",{"date":495,"type":42},"2023-08-16",{"date":497,"type":19},"2023-08",{"date":499,"type":19},"2028-12",{"name":501,"class":502},"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","INDUSTRY",3,{"id":505,"slug":506,"hasResults":11,"nctId":507,"briefTitle":508,"officialTitle":508,"acronym":4,"eligibilityCriteria":509,"healthyVolunteers":11,"sex":15,"minAge":86,"maxAge":510,"enrollmentInfo":511,"targetDuration":513,"studyType":20,"phases":4,"briefSummary":514,"conditions":515,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":523,"locationsCount":48},"100275772","institut-paoli-calmettes-thyroid-cancer-database-100275772","NCT02869620","Institut Paoli Calmettes Thyroid Cancer Database","Inclusion Criteria:\n\n* Diagnosis of thyroid cancer\n\nExclusion Criteria:\n\n* Non applicable","95 Years",{"count":512,"type":19},3000,"10 Years","Database of Institut Paoli-Calmettes patients diagnosed with thyroid cancer",[24],"2016-08-16",{"date":518,"type":19},"2016-08-17",{"date":520,"type":4},"2010-01",{"date":522,"type":19},"2030-12",{"name":524,"class":77},"Institut Paoli-Calmettes"]